DE1251767B - Verfahren zur Herstellung von neuen m 6 Stellung substituierten 5 6 Dihydro-5oxo HH pyrido[2,3-b] [l,5]benzodiazepinen - Google Patents
Verfahren zur Herstellung von neuen m 6 Stellung substituierten 5 6 Dihydro-5oxo HH pyrido[2,3-b] [l,5]benzodiazepinenInfo
- Publication number
- DE1251767B DE1251767B DE1964T0025723 DET0025723A DE1251767B DE 1251767 B DE1251767 B DE 1251767B DE 1964T0025723 DE1964T0025723 DE 1964T0025723 DE T0025723 A DET0025723 A DE T0025723A DE 1251767 B DE1251767 B DE 1251767B
- Authority
- DE
- Germany
- Prior art keywords
- pyrido
- dihydro
- general formula
- benzodiazepine
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 19
- 229940049706 benzodiazepine Drugs 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 3
- 150000001557 benzodiazepines Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 13
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 150000001339 alkali metal compounds Chemical class 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 231100001274 therapeutic index Toxicity 0.000 description 5
- 239000003513 alkali Substances 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical group N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- VYLLJAKCYFLTGT-UHFFFAOYSA-N 6-(2-methylpropyl)-11h-pyrido[3,2-c][1,5]benzodiazepin-5-one Chemical compound O=C1N(CC(C)C)C2=CC=CC=C2NC2=NC=CC=C21 VYLLJAKCYFLTGT-UHFFFAOYSA-N 0.000 description 1
- NJFAYUFRHYLWIF-UHFFFAOYSA-N 6-ethyl-11h-pyrido[3,2-c][1,5]benzodiazepin-5-one Chemical compound O=C1N(CC)C2=CC=CC=C2NC2=NC=CC=C21 NJFAYUFRHYLWIF-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- -1 aromatic sulfonic acid ester Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1964T0025723 DE1251767B (de) | 1964-02-28 | 1964-02-28 | Verfahren zur Herstellung von neuen m 6 Stellung substituierten 5 6 Dihydro-5oxo HH pyrido[2,3-b] [l,5]benzodiazepinen |
| US434666A US3326900A (en) | 1964-02-28 | 1965-02-23 | Novel 5, 6-dihydro-11h-pyrido[2, 3-b][1, 5]benzodiazepines |
| FR6891A FR1458125A (fr) | 1964-02-28 | 1965-02-24 | Procédé pour préparer des 5, 6-dihydro-11h-pyrido [2, 3-b] [1, 5] benzo-diazépines |
| CH248765A CH453374A (de) | 1964-02-28 | 1965-02-24 | Verfahren zur Herstellung von neuen 5,6-Dihydro-11H-pyrido(2,3-b) (1,5)benzodiazepinen |
| GB8456/65A GB1071757A (en) | 1964-02-28 | 1965-02-26 | 5,6-dihydro-11,h-pyrido-[2,3-d] [1,5]-benzodiazepines |
| FR16186A FR4999M (enExample) | 1964-02-28 | 1965-05-07 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1964T0025723 DE1251767B (de) | 1964-02-28 | 1964-02-28 | Verfahren zur Herstellung von neuen m 6 Stellung substituierten 5 6 Dihydro-5oxo HH pyrido[2,3-b] [l,5]benzodiazepinen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1251767B true DE1251767B (de) | 1968-04-18 |
Family
ID=7552265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1964T0025723 Pending DE1251767B (de) | 1964-02-28 | 1964-02-28 | Verfahren zur Herstellung von neuen m 6 Stellung substituierten 5 6 Dihydro-5oxo HH pyrido[2,3-b] [l,5]benzodiazepinen |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US3326900A (enExample) |
| CH (1) | CH453374A (enExample) |
| DE (1) | DE1251767B (enExample) |
| FR (2) | FR1458125A (enExample) |
| GB (1) | GB1071757A (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH438343A (de) * | 1962-11-08 | 1967-06-30 | Thomae Gmbh Dr K | Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen |
| GB1156781A (en) * | 1965-04-07 | 1969-07-02 | Lab U P S A | New Heterocyclic Compounds |
| US3475414A (en) * | 1966-12-05 | 1969-10-28 | Miles Lab | Tetrahydro-1-benzazepin-2(1h)-one derivatives |
| FI50242C (fi) * | 1969-07-18 | 1976-01-12 | Thomae Gmbh Dr K | Menetelmä valmistaa farmakologisesti aktiivisia uusia diallyyliaminoal kanoyylidibenso- tai pyridobenso-diatsepiineja ja niiden happoadditios uoloja. |
| US5602113A (en) * | 1991-02-07 | 1997-02-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyridobenzo- and pyridiothieno-diazepines useful for the treatment of HIV infection |
| US5686445A (en) * | 1993-07-29 | 1997-11-11 | American Cyanamid Company | Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists |
| AU8592598A (en) * | 1997-07-30 | 1999-02-22 | Wyeth | Tricyclic vasopressin agonists |
| US7138393B2 (en) * | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| FR2850654A1 (fr) * | 2003-02-03 | 2004-08-06 | Servier Lab | Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3025246B1 (fr) | 2014-08-29 | 2016-12-09 | Snecma | Roue aubagee a calages variables |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA658624A (en) * | 1963-02-26 | Schmutz Jean | Diazepine derivatives | |
| US3038896A (en) * | 1958-05-30 | 1962-06-12 | Cilag Chemie | 1-(di-lower alkyl amino lower alkyl thio lower alkyl)-aza-[2, 3:5, 6]-dibenzocycloheptadiene compounds |
| US3150125A (en) * | 1959-09-22 | 1964-09-22 | Wander Ag Dr A | 5-(basic substituted)-10, 11-dihydro-11-oxo-5h-dibenzo[b, e][1, 4]diazepine compounds |
-
1964
- 1964-02-28 DE DE1964T0025723 patent/DE1251767B/de active Pending
-
1965
- 1965-02-23 US US434666A patent/US3326900A/en not_active Expired - Lifetime
- 1965-02-24 CH CH248765A patent/CH453374A/de unknown
- 1965-02-24 FR FR6891A patent/FR1458125A/fr not_active Expired
- 1965-02-26 GB GB8456/65A patent/GB1071757A/en not_active Expired
- 1965-05-07 FR FR16186A patent/FR4999M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US3326900A (en) | 1967-06-20 |
| FR1458125A (fr) | 1966-11-10 |
| GB1071757A (en) | 1967-06-14 |
| FR4999M (enExample) | 1967-04-17 |
| CH453374A (de) | 1968-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2516040C2 (de) | Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE2238504C3 (de) | l-Phenoxy-S-alkylaminopropan^-ol -Derivate | |
| DE2062001C2 (de) | 1,2,3,4-Tetrahydro-4-phenylisochinolin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und pharmazeutisches Präparat | |
| DE2837161A1 (de) | Neue benzimidazole und deren verwendung | |
| DE3324115A1 (de) | Neue imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel | |
| DE1251767B (de) | Verfahren zur Herstellung von neuen m 6 Stellung substituierten 5 6 Dihydro-5oxo HH pyrido[2,3-b] [l,5]benzodiazepinen | |
| DE2427943C2 (de) | Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE2523103C3 (de) | Substituierte 2-[N-Progargyl-N-(2-chlorphenyl)amino] -imidazoline-^), deren Säureadditionssalze, Verfahren zu ihrer Herstellung und deren Verwendung | |
| DE2503407A1 (de) | Tetracyclische piperidinderivate | |
| DE3346575A1 (de) | Neue benzimidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel | |
| DE1668634B2 (enExample) | ||
| DE3118521A1 (de) | Dibenzo(de,g)chinolin-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkaeltungskrankheiten und allergien | |
| DE2051962A1 (de) | Benzimidazo eckige Klammer auf l,2d eckige Klammer zu eckige Klammer auf 1,4 eckige Klammer zu benzodiazepin 6 (5H) one und Verfahren zu deren Her stellung | |
| DE2459629A1 (de) | Pyrimidinoaminoaethylergolin-derivate und verfahren zu ihrer herstellung | |
| DE1470367A1 (de) | Verfahren zur Herstellung von in 5-Stellung substituierten 5,6-Dihydro-6-oxopyrido[2,3-b][1,4]benzoxazepinen | |
| DE2403786A1 (de) | Neue derivate der cumarine | |
| CH461489A (de) | Verfahren zur Herstellung von neuen Oxazolderivaten | |
| DE2232098A1 (de) | 2-alkyl-4(3h)-pteridinone und verfahren zu ihrer herstellung | |
| DE2435381C2 (de) | 8-(2-Dimethylaminoäthyl)-3-oxo-4-phenyl-1-thia-4,8-diazaspiro[4.5]decan und seine Salze mit Säuren, Verfahren zu ihrer Herstellung und deren Verwendung in Arzneipräparaten | |
| DE2237502A1 (de) | Neue heterocyclische verbindungen und verfahren zu deren herstellung | |
| DE1620572B1 (de) | Pyrido Ä2,3-bÜ Ä1,4Ü benzodiazepinderivate und ein Verfahren zu ihrer Herstellung | |
| DE1147946B (de) | Verfahren zur Herstellung von Phenthiazinderivaten und ihren Saeureadditionssalzen | |
| DE1090215B (de) | Verfahren zur Herstellung von Phenthiazinderivaten | |
| DE2360852A1 (de) | Neue azabenzo-1,5-diazepine | |
| DE3016303C2 (de) | 1,2-Dihydropyrido[2,3-e]-1,2,4-triazinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |